Compass Therapeutics announced participation in two healthcare investor conferences in December 2025, highlighting their ongoing clinical-stage oncology research focused on antibody-based therapeutics targeting tumor growth and immune system interactions.

Compass Therapeutics will participate in multiple healthcare and investment conferences in September 2025, including events in Boston and New York, presenting their oncology-focused antibody-based therapeutics research.

Compass Therapeutics plans to raise approximately $120 million through a public offering of 33,290,000 common stock shares and pre-funded warrants at $3.00 per share, with the proceeds intended for research, clinical development, and corporate purposes.

Compass Therapeutics plans to launch an underwritten public offering of common stock and pre-funded warrants to fund research, clinical development, and commercial readiness preparations.

Three companies with recent stock rallies that analysts remain bullish on are Compass Therapeutics, Amprius Technologies, and Allot Communications. Analysts see significant upside potential in these momentum stocks despite their recent gains.

Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in September 2024, where it will present updates on its oncology-focused pipeline of antibody-based therapeutics.

Eliem Therapeutics announced the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development. The new executives bring extensive experience in the pharmaceutical and biotechnology industries, which will help Eliem advance its pipeline of therapeutics for autoimmune-driven inflammatory diseases.

Compass Therapeutics, a clinical-stage biopharmaceutical company, announced that it will present at the Wedbush PacGrow Healthcare Conference on August 13, 2024. The company is developing proprietary antibody-based therapeutics to treat multiple human diseases, with a focus on the relationship between angiogenesis, the immune system, and tumor growth.

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024.

BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024.

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced an upcoming poster presentation of its novel anti-CD137 agonist antibody, CTX-471, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) --  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024.